Eric Laffon (E Laffon)

Publication Activity (10 Years)

Years Active: 2017-2022
Publications (10 Years): 16

Top Topics

Metastatic Colorectal Cancer

Ankylosing Spondylitis

Metal Organic Framework

Top Venues

European journal of nuclear medicine and molecular imaging

EJNMMI research

Cancer biotherapy & radiopharmaceuticals

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Eric Laffon, Henri de Clermont, Roger Marthan
On the factors affecting the liver SUV in [ 18 F]FDG PET/CT imaging. European journal of nuclear medicine and molecular imaging (2022)
Eric Laffon, Roger Marthan
Estimation of Cumulative Activity of 177 Lu-Cetuximab from a Single Diagnostic 64 Cu-Cetuximab Scan. Cancer biotherapy & radiopharmaceuticals 37 (5) (2022)
Eric Laffon, Roger Marthan
64 Cu-/ 177 Lu-Cetuximab Theranostic Pair: May the Single 64 Cu-Cetuximab Diagnostic Scan Be Acquired at Any Time After Injection? Cancer biotherapy & radiopharmaceuticals (2022)
Eric Laffon, Henri de Clermont, Roger Marthan
An abbreviated therapy-dosimetric equation for the companion diagnostic/therapeutic [64/67Cu]Cu-SARTATE. EJNMMI research 11 (1) (2021)
Eric Laffon, Roger Marthan
On Semi-quantitative Methods for Assessing Vascular 18FDG-PET Activity in Large-Vessels Vasculitis. Journal of nuclear medicine : official publication, Society of Nuclear Medicine (2021)
Eric Laffon, Roger Marthan
Is There a Relevant Imaging Time for Optimal Quantitative 89Zr-DFO-Daratumumab PET Imaging? Radiology 299 (3) (2021)
Eric Laffon, Roger Marthan
Is Patlak y-intercept a relevant metrics? European journal of nuclear medicine and molecular imaging 48 (5) (2021)
Eric Laffon, Roger Marthan
SUR for mediastinal metastatic lymph node status in non-small-cell lung cancer patients. European journal of nuclear medicine and molecular imaging 47 (12) (2020)
Eric Laffon, Sébastien Buj, Henri de Clermont, Roger Marthan
Fitting of late dynamic [18F]MK6240 PET scans for in vivo tau quantification. European journal of nuclear medicine and molecular imaging 47 (1) (2019)
Eric Laffon, Roger Marthan
Could we avoid computing TMTV of DLBCL patients in routine practice? European journal of nuclear medicine and molecular imaging 45 (12) (2018)
Eric Laffon, Henri de Clermont, Sébastien Buj, Roger Marthan
Should we assess repeatability of PET quantitative uptake measurements of each 18F-labelled tracer? European journal of nuclear medicine and molecular imaging 45 (7) (2018)
Eric Laffon, Roger Marthan
Optimal method for measuring baseline metabolic tumor volume in DLBCL patients: are statistical agreements of SUV ≥2.5 satisfactory? European journal of nuclear medicine and molecular imaging 45 (10) (2018)
Eric Laffon, Roger Marthan
Performance of 18F-FDG PET/MRI and 18F-FDG PET/CT for T and N staging in patients with non-small-cell lung cancer. European journal of nuclear medicine and molecular imaging 46 (2) (2018)
Eric Laffon, M L Calcagni, G Galli, A Giordano, A Capotosti, R Marthan, L Indovina
Comparison of three-parameter kinetic model analysis to standard Patlak's analysis in 18F-FDG PET imaging of lung cancer patients. EJNMMI research 8 (1) (2018)
Eric Laffon, Henri de Clermont, Roger Marthan, Fredéric Paycha
On the 18F-fluoride PET imaging quantification to predict 223Ra-dichloride treatment response. European journal of nuclear medicine and molecular imaging 45 (2) (2017)
Eric Laffon, Roger Marthan
FDG PET for therapy monitoring in Hodgkin's and non-Hodgkin's lymphomas: qPET versus rPET. European journal of nuclear medicine and molecular imaging 44 (9) (2017)